SCHEMBL3247075

SCHEMBL3247075

CC1(CNC(=O)c2ccccc2C(=O)O)NC(=O)NC1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAMTS5 Q9UNA0 5/20 0.48
ADAMTS4 O75173 2/20 0.48
ADAM17 P78536 1/20 0.48
MMP2 P08253 2/20 0.47
MMP3 P08254 1/20 0.47
MMP12 P39900 1/20 0.47
MMP13 P45452 1/20 0.47
KMT2A Q03164 2/20 0.47
APEX1 P27695 1/20 0.47
HTT P42858 1/20 0.45
KDM4E B2RXH2 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
ALDH1A1 P00352 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
ADAMTS7 Q9UKP4 1/20 0.40
KCNA3 P22001 1/20 0.39
USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12416690 0.80 ADAM17 (0.57) ADAMTS5ADAMTS4ADAM17MMP2MMP3
SCHEMBL12378634 0.77 ADAM17 (0.56) ADAMTS5ADAMTS4ADAM17MMP2MMP3
SCHEMBL4056808 0.77 ADAM17 (0.62) ADAMTS5ADAMTS4ADAM17MMP2MMP3
SCHEMBL23354305 0.77 ADAMTS7 (0.69) ADAMTS7
SCHEMBL23354303 0.76 ADAMTS5 (0.51) ADAMTS5ADAMTS4ADAM17MMP2MMP3
SCHEMBL23366966 0.74 ADAMTS7 (0.53) ADAMTS5ADAMTS4ADAM17MMP2MMP3
SCHEMBL23371316 0.74 ADAMTS7 (0.53) ADAMTS5ADAMTS4ADAM17MMP2MMP3
SCHEMBL7913239 0.71 ADAMTS5 (0.44) ADAMTS5ADAMTS4ADAM17MMP2MMP3
SCHEMBL10158103 0.70 HTT (0.68) KMT2AAPEX1HTTKDM4ETAAR1
SCHEMBL6268376 0.69 KMT2A (0.65) KMT2AAPEX1HTTKDM4ETAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2341777-B1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS NOVABAY PHARMACEUTICALS INC (US) 2015-01-21 EP disclosed
EP-2341777-B1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS NOVABAY PHARMACEUTICALS INC (US) 2015-01-21 EP disclosed
US-8722715-B2 Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions NovaBay Pharmaceuticals (US) 2014-05-13 US disclosed
US-8722715-B2 Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions NovaBay Pharmaceuticals (US) 2014-05-13 US disclosed
US-7998961-B2 For treating conditions associated with UDP-3-O (R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) SCHERING CORPORATION (US) 2011-08-16 US disclosed
US-7998961-B2 For treating conditions associated with UDP-3-O (R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) SCHERING CORPORATION (US) 2011-08-16 US disclosed
US-20100137349-A1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS NOVABAY PHARMACEUTICALS, INC. 2010-06-03 US disclosed
US-20100137349-A1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS NOVABAY PHARMACEUTICALS, INC. 2010-06-03 US disclosed
US-20100137349-A1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS NOVABAY PHARMACEUTICALS, INC. 2010-06-03 US disclosed
WO-2010054009-A1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS NOVABAY PHARMACEUTICALS, INC. (US) 2010-05-14 WO disclosed
US-20080226618-A1 HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS SCHERING CORPORATION 2008-09-18 US disclosed
US-20080226618-A1 HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS SCHERING CORPORATION 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080226618-A1 HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS LPXN, HAX1, LCT ADAMTS5 3194/4885ADAMTS4 3629/4885ADAM17 1995/4885
US-20100137349-A1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS OXA1L, NISCH, ODC1 ADAMTS5 3688/4885ADAMTS4 4291/4885ADAM17 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.